Why the study?
Does candesartan reduce cardiovascular mortality and morbidity in patients with chronic heart failure?
Population
Patients with chronic heart failure, including those intolerant to angiotensin-converting enzyme inhibitors…
Design
Review
Authors
Loading...
Supports candesartan in heart failure overall; leaves open definitive benefit in preserved ejection fraction pending larger trials.
Does candesartan reduce cardiovascular mortality and morbidity in patients with chronic heart failure?
This review highlights that candesartan is an effective therapy for reducing cardiovascular mortality and morbidity across a broad spectrum of heart failure patients.
Robert S. McKelvie (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: